epharma logo

Climavit

BANNER 2018 INTERNALPAGEOLD2

Genistein (soy isoflavon) has a recognised activity on vasomotor symptoms;
Agnus castus is active on flushing and on psychological symptoms;
Hawthorn is active on psychoaffective symptoms, particularly anxiety, irritability and mood;
Vitamin D3 and Calcium favour the trophism and the mineralisation of osseous tissue.

CLIMAVIT® exploits the synergy of Genistein, Vitex Agnus Castus and Hawthorn to help hot flushing and nocturnal sweating mitigation as well as night time sleep quality.

 

INDICATIONS

CLIMAVIT® is a food supplement, available as orally disintegrating granules (in stick) and soluble granules (in sachet), for the wellness of the woman in menopause and in case of increased need of minerals or decreased intake with the diet.

HOW TO USE

1 sachet or stick per day is recommended
The odg should be dissolved directly in the mouth.
The soluble granules should be dissolved in a glass of water.

- gluten free
- lactose free
- sugar free

 

Ingredients Content for
sachet/stick
% RNV*
Genistein (isoflavon) 80 mg  
Agnus castus (Vitex agnus-castus L., fruits) dry extract 40 mg  
Hawthorn (Crataegus oxyacantha auct., leafs and flowers) dry extract (min. 1.8% vitexin) 300 mg  
Vitamin D3 5 µg 100%
Calcium** 240 mg 30%
     

(*) % Reference Nutrient Values - (**) for ODG Calcium content is 120mg (%RNV 15%)

 

CLINICAL DATA

Efficacy and safety of CLIMAVIT® have been under evaluation in a preliminary, observational, clinical study, in which menopause women presenting more than 5 moderate flushing per day concomitantly with an anxious state or sleep disorders, not so severe to require pharmacologic therapy, were recruited.
The women on treatment with hormonal replacement therapy or other products taken for the relief of symptoms under evaluation, were excluded [De Leo et al. 2017].

 

CLIMAVIT® administered orally at the dose of 1 sachet/day for at least 12 weeks. At baseline, after 6 and 12 weeks from start of the treatment, the Kupperman Index is calculated considering the severity of flusing, nocturnal sweating, insomnia, irritability, depressed mood or melancholia, dizziness, fatigue, muscular and articular pain, headache, palpitations and paresthesias.
Vaginal dryness, dyspareunia, anxiety and libido loss are determined at start and the end of the treatment.


Phytosurveillance: any adverse reaction or unwanted event is recorded in the Case report form, specifying severity, duration, onset time, relationship with the treatment and the action taken.